Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …

Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …

Conformational dynamics of viral envelope proteins seem to be involved in mediating
evasion from neutralizing antibodies (NAbs) by mechanisms that limit exposure of …

Great strides have been made in understanding and treating hepatitis C virus (HCV) thanks
to the development of various experimental systems including cell-culture-proficient HCV …

Even 30 years after the discovery of the hepatitis C virus (HCV) in humans there is still no
vaccine available. Reasons for this include the high mutation rate of HCV, which allows the …

An effective vaccine for hepatitis C virus (HCV) is a major unmet need, and it requires an
antigen that elicits immune responses to key conserved epitopes. Based on structures of …

A hepatitis C virus (HCV) vaccine is urgently needed. Vaccine development has been
hindered by HCV's genetic diversity, particularly within the immunodominant hypervariable …

Hepatitis C virus (HCV) is a serious and growing public health problem despite recent
developments of antiviral therapeutics. To achieve global elimination of HCV, an effective …

Summary Whether hypervariable region 1 (HVR1)-targeting antibodies elicited during
natural hepatitis C virus (HCV) infection contribute to virus clearance and what is the …